First Patient Enrolled in BrainStorm's Phase II ALS Trial
Complete the form below to unlock access to ALL audio articles.
BrainStorm Cell Therapeutics has announced that the first patient was enrolled in its Phase II ALS trial at Massachusetts General Hospital (MGH) in Boston.
BrainStorm’s Phase II trial is a randomized, double-blind, placebo controlled multi-center study designed to evaluate the safety and efficacy of transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors ("MSC-NTF" or NurOwn™) in 48 ALS patients.
The trial is also being conducted at the University of Massachusetts Memorial (UMass) Hospital in Worcester, MA and the Mayo Clinic in Rochester, Minnesota.